Bostwick Therapeutics

Bostwick Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for fibrotic disorders, with a primary focus on Dupuytren's contracture. The company's lead candidate utilizes botulinum toxin type A to target myofibroblasts, aiming to reduce the physical tension and contracture associated with the disease without the need for invasive surgery. Founded by renowned pathologist Dr. David Bostwick, the firm seeks to expand its application of neurotoxins to other fibroproliferative conditions such as Ledderhose and Peyronie's diseases. Their approach represents a shift toward non-enzymatic, tension-based intervention in the management of hand and connective tissue deformities. The company is currently advancing its lead program through Phase 2 clinical trials to demonstrate efficacy in improving range of motion and reducing cord thickness.